We recently showed that pharmacological inhibition of the catalytic activity of METTL3, using the first-in-class small molecule STM2457, is a novel therapeutic strategy against acute myeloid leukaemia (AML) [5]. The gene discussed is METTL3; the disease is acute myeloid leukemia.